Rebecca Berdeaux, PhD, joins CellChorus as Vice President of Science

Dr. Berdeaux is an expert in cell signaling, energy metabolism, and skeletal muscle regeneration

PRESS RELEASE

HOUSTON, Texas & SAN CARLOS, Calif. — September 8, 2022 — CellChorus®, the leader in applying artificial intelligence to visually evaluate how individual cells perform over time, announced the addition of Rebecca Berdeaux, PhD, as Vice President of Science.

“Dr. Berdeaux has a strong track record of scientific achievement applying multidisciplinary approaches to answer important biomedical questions,” said Daniel Meyer, CEO of CellChorus. “We are excited to have recruited a leader with her depth of scientific and team-building experience.”

“I have spent my career studying how cells sense and respond to each other in order to understand fundamentals of oncogenesis, metabolic disorders, and tissue regeneration,” said Dr. Berdeaux. “To identify new molecular pathways and develop new treatments, we must understand the dynamics of individual cell-cell interactions. I am excited to join the CellChorus team because the TIMING platform offers the potential to improve basic research in nearly every area of life sciences. The TIMING platform offers unique opportunities to propel preclinical studies as well as the clinical development and manufacturing of cell therapeutics to address unmet needs in oncology, infectious diseases, autoimmune disorders, and many other diseases.”*

Dr. Berdeaux is an expert in cell signaling, energy metabolism, and skeletal muscle regeneration. Prior to joining CellChorus, she focused on research and medical education as a tenured Associate Professor of Integrative Biology and Pharmacology with McGovern Medical School at UTHealth Houston, where she retains a faculty position and laboratory. She previously served as the Director of the Graduate Program in Biochemistry and Cell Biology at The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, and as Adjunct Faculty at the Diabetes Research Center in the Department of Medicine at Baylor College of Medicine. Dr. Berdeaux conducted postdoctoral studies in Molecular Physiology at The Salk Institute for Biological Studies. She earned a PhD in Molecular and Cell Biology from the University of California, Berkeley; and a BS in Biology from the University of Illinois, Urbana-Champaign.

About CellChorus

CellChorus is the leader in applying artificial intelligence to visually evaluate how thousands of individual cells, such as T cells and NK cells, perform over time. The company applies Timelapse Imaging Microscopy in Nanowell Grids (TIMING™) with neural network-based detection to identify cells and evaluate their activity, including how they move, activate, kill and survive. The patent protected CellChorus platform links TIMING data and insight with information from other analysis modalities such as single-cell RNA sequencing and flow cytometry to provide a comprehensive understanding of cellular function, state and phenotype for the life sciences industry. Please visit cellchorus.com for more information.

Company Contact:
Daniel Meyer
Chief Executive Officer
CellChorus
TIMING@cellchorus.com

*Views expressed by Dr. Berdeaux do not reflect the views of UTHealth Houston.